Molecular Biology Reports

, Volume 39, Issue 2, pp 797–803 | Cite as

An intronic polymorphism rs2237062 in the CXCL14 gene influences HBV-related HCC progression in Chinese population

  • Xing Gu
  • Hao Wang
  • Aihua Wang
  • Tonghai Dou
  • Peng Qi
  • Qiang Ji
  • Hui Li
  • Chunfang Gao
Article

Abstract

CXCL14 (C-X-C motif chemokine ligand 14) is a conserved member of chemokine family and functions as a chemoattractant for multiplicate immunocytes. CXCL14 expression is constitutive in normal tissues, but absent in wide range of epithelial tumors. Many reports have claimed its important role in tumorigenesis and vascularization. An association between rs2237062 polymorphism and hepatocellular carcinoma (HCC) susceptibility was found in patients with chronic HCV infection in Japanese population. Here we analyzed, by using a polymerase chain reaction-ligation detection reaction (PCR-LDR), the polymorphism in 202 non-HCC patients with HBV infection, 361 HBV-related HCC patients and 407 healthy controls. The aim was to detect the possible association of this single-nucleotide polymorphism (SNP) with HBV-related HCC susceptibility and progression. However, no association was found between rs2237062 polymorphism and susceptibility to HBV infection or HBV-related HCC. Intriguingly, our stratification analysis revealed that HBV-related HCC patients in advanced phase (TNM-II–IV stage) had significantly higher C allele frequency at this polymorphism than patients at early stage (TNM-I stage) (33.5% vs. 25.7%), and its odds ratio reached 1.47 (95% CI 1.06–2.04, P = 0.021). These results suggest that the rs2237062 polymorphism in the CXCL14 gene might influence HBV-related HCC progression in Chinese population.

Keywords

CXCL14 HBV-related HCC SNP TNM stage Tumor progression 

Supplementary material

11033_2011_801_MOESM1_ESM.jpg (1.4 mb)
Supplementary material 1 (JPEG 1399 kb)
11033_2011_801_MOESM2_ESM.jpg (1.4 mb)
Supplementary material 2 (JPEG 1417 kb)

References

  1. 1.
    Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4:540–550PubMedCrossRefGoogle Scholar
  2. 2.
    Johrer K, Pleyer L, Olivier A et al (2008) Tumour-immune cell interactions modulated by chemokines. Expert Opin Biol Ther 8:269–290PubMedCrossRefGoogle Scholar
  3. 3.
    Hromas R, Broxmeyer HE, Kim C et al (1999) Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun 255:703–706PubMedCrossRefGoogle Scholar
  4. 4.
    Frederick MJ, Henderson Y, Xu X et al (2000) In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 156:1937–1950PubMedCrossRefGoogle Scholar
  5. 5.
    Cao X, Zhang W, Wan T et al (2000) Molecular cloning and characterization of a novel CXC chemokine macrophage inflammatory protein-2 gamma chemoattractant for human neutrophils and dendritic cells. J Immunol 165:2588–2595PubMedGoogle Scholar
  6. 6.
    DeVries ME, Kelvin AA, Xu L, Ran L, Robinson J, Kelvin DJ (2006) Defining the origins and evolution of the chemokine/chemokine receptor system. J Immunol 176:401–415PubMedGoogle Scholar
  7. 7.
    Shurin GV, Ferris RL, Tourkova IL et al (2005) Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol 174:5490–5498PubMedGoogle Scholar
  8. 8.
    Starnes T, Rasila KK, Robertson MJ et al (2006) The chemokine CXCL14(BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp Hematol 34:1101–1105PubMedCrossRefGoogle Scholar
  9. 9.
    Nara N, Nakayama Y, Okamoto S et al (2007) Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance. J Biol Chem 282:30794–30803PubMedCrossRefGoogle Scholar
  10. 10.
    Takahashi M, Takahashi Y, Takahashi K et al (2007) CXCL14 enhances insulin-dependent glucose uptake in adipocytes and is related to high-fat diet-induced obesity. Biochem Biophys Res Commun 364:1037–1042PubMedCrossRefGoogle Scholar
  11. 11.
    Kurth I, Willimann K, Schaerli P, Hunziker T, Clark-Lewis I, Moser B (2001) Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med 194:855–861PubMedCrossRefGoogle Scholar
  12. 12.
    Schwarze R, DePrimo SE, Grabert LM, Fu VX, Brooks JD, Jarrard DF (2002) Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem 277:14877–14883PubMedCrossRefGoogle Scholar
  13. 13.
    Shellenberger TD, Wang M, Gujrati M et al (2004) BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res 64:8262–8270PubMedCrossRefGoogle Scholar
  14. 14.
    Kato N, Ji G, Wang Y et al (2005) Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology 42:846–853PubMedCrossRefGoogle Scholar
  15. 15.
    Robinson WS (1995) Hepatitis B virus and hepatitis D virus. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases, 4th edn. Churchill Livingstone, New York, pp 1406–1439Google Scholar
  16. 16.
    Sun H, Chua MS, Yang D, Tsalenko A, Peter BJ, So S (2008) Antibody arrays identify potential diagnostic markers of hepatocellular carcinoma. Biomark Insights 3:1–18PubMedGoogle Scholar
  17. 17.
    Sobin LH, Wittekind CL (eds) (2002) TNM classification of malignant tumors, 6th edn. John Wiley & Sons, New YorkGoogle Scholar
  18. 18.
    Peterson FC, Thorpe JA, Harder AG, Volkman BF, Schwarze SR (2006) Structural determinants involved in the regulation of CXCL14/BRAK expression by the 26S proteasome. J Mol Biol 363:813–822PubMedCrossRefGoogle Scholar
  19. 19.
    Schaerli P, Willimann K, Ebert LM, Walz A, Moser B (2005) Cutaneous CXCL14 targets blood precursors to epidermal niches for langerhans cell differentiation. Immunity 23:331–342PubMedCrossRefGoogle Scholar
  20. 20.
    Schwarze SR, Luo J, Isaacs WB, Jarrard DF (2005) Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 64:67–74PubMedCrossRefGoogle Scholar
  21. 21.
    Ozawa S, Kato Y, Komori R et al (2006) BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochem Biophys Res Commun 348:406–412PubMedCrossRefGoogle Scholar
  22. 22.
    Martin A, Christina H, Eleonor O et al (2009) CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci USA 106:3414–3419CrossRefGoogle Scholar
  23. 23.
    Wente MN, Mayer C, Gaida MM et al (2008) CXCL14 expression and potential function in pancreatic cancer. Cancer Lett 259:209–217PubMedCrossRefGoogle Scholar
  24. 24.
    Popper H, Gerber MA, Thung SN (1982) The relation of hepatocellular carcinoma to infection with hepatitis B and related viruses in man and animals. Hepatology 2:1S–9SCrossRefGoogle Scholar
  25. 25.
    Beasley RP, Hwang LY, Lin CC, Chien CS (1981) Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet 2:1129–1133PubMedCrossRefGoogle Scholar
  26. 26.
    Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37:S4–S66PubMedCrossRefGoogle Scholar
  27. 27.
    Dickinson JA, Wun YT, Wong SL (2002) Modelling death rates for carriers of hepatitis B. Epidemiol Infect 128:83–92PubMedCrossRefGoogle Scholar
  28. 28.
    Gu X, Qi P, Zhou F et al (2010) An intronic polymorphism in the corticotropin-releasing hormone receptor 2 gene increases susceptibility to HBV-related hepatocellular carcinoma in Chinese population. Hum Genet 127:75–81PubMedCrossRefGoogle Scholar
  29. 29.
    Gu X, Qi P, Zhou F et al (2010) +49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol 71:83–87PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Xing Gu
    • 1
  • Hao Wang
    • 2
  • Aihua Wang
    • 1
  • Tonghai Dou
    • 3
  • Peng Qi
    • 1
  • Qiang Ji
    • 1
  • Hui Li
    • 1
  • Chunfang Gao
    • 1
  1. 1.Department of Laboratory MedicineEastern Hepatobiliary Hospital, Second Military Medical UniversityShanghaiPeople’s Republic of China
  2. 2.Department of Laboratory MedicineChangzheng Hospital, Second Military Medical UniversityShanghaiPeople’s Republic of China
  3. 3.Institutes of Biomedical SciencesFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations